Aerovance, a Berkeley, Calif biopharmaceutical company looking to find a partner for its asthma treatement, Aerovant, reached back to year-old news and announced it has finished raising $60 million in a third round of financing.
There is “substantial very, very strong interest” by pharmaceutical and biotech companies in the asthma treatment, the company told VentureWire (sub required), though no specifics were given.
Here is the company’s announcement of the funding last year.
The company’s drugs target severe respiratory and inflammatory diseases. The financing was led by Clarus Ventures, and included Alta Partners and existing investors Apax Partners, Lehman Brothers, NGN Capital and Burrill & Co.
Aerovance received $28 million of the funding last year, and has since received an additional $32 million.